The global gene synthesis market is expected to grow at a sturdy rate of 19.2% during the forecast period. In 2023, the market valuation is expected to be at USD 779.4 million. By 2033, the estimation is projected to cross USD 4.5 billion.
Key factors supporting the market growth are:
The ability to synthesize whole genes, metabolic pathways and even genomes has become possible in the last 30 years. Genetic engineering has evolved into a gene synthesis process that creates double-stranded DNA from oligonucleotides using different assembly methods into plasmids for transfection. The evolution has certainly assisted healthcare experts in predicting the pathogen behaviour before it becomes a serious cause of concern.
Various methods are currently used based on DNA complexity and length. The researchers are also in the process of developing a system which processes several samples automatically. To maintain the brand value, the manufacturers are laying a lot of emphasis on Intellectual Property Rights.
EVONETIX LTD has announced that a European patent has been granted for its proprietary Binary Assembly method in gene synthesis. As a result of the patent (EP 3688189 B1), Evonetix has further enhanced its IP portfolio and enabled a new generation of in-lab DNA synthesis platforms. The platform would simplify gene synthesis for researchers. Using the patented method, long DNA molecules can be assembled on-chip, and synthesis errors can be eliminated.
Synthetic genes can be produced at the molecular biology bench using common reagents and procedures, despite their easy availability. Researchers are working hard to develop long DNA molecules in the future. This is believed to assist in producing DNA sequences and proper protein production.
The surging geriatric population is expected to increase the demand for gene synthesis machines. It is crucial in treating many diseases during ageing and helps diagnose. The market has been surging with therapeutic advancements, opening new prospects for gene synthesis. The synthesis of genes and cloning are meant to reduce time and cost. These factors have led government authorities and private enterprises to invest in this technique.
Asia Pacific is expected to grab the lion’s share of the market. New opportunities for biological functionality were found in developing countries throughout the Asia Pacific region, which prompted the introduction of gene synthesis. This region continues to see a rise in geriatrics, as well as an increase in the replication of DNA. The demand for gene synthesis will continue to increase in this region as disposal incomes rise and high-quality healthcare systems expand.
| Attributes | Value |
|---|---|
| Gene Synthesis Market Value (2022) | USD 643.2 million |
| Gene Synthesis Market Expected Value (2023) | USD 779.4 million |
| Gene Synthesis Market Forecast Value (2033) | USD 4.5 billion |
| Gene Synthesis Market Expected CAGR (2023 to 2033) | 19.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The massive expansion of biotechnology and gene research analysis, in particular, has opened new venues for research. With scientists conducting in-depth research on DNA sequences to study the evolution of human beings, the adoption of gene synthesis is expected to surge.
This method is also used in the current research works, which are based on increasing the lifespan of human beings. With so much significance, the market has been displaying robust growth. However, the market might witness a little slump owing to the lockdown and supply chain disruption. While the historical CAGR for the market was 19.9%, the anticipated CAGR is 19.2%.
CRISPR-based therapeutics can be adapted in near-limitless ways using a new gene editing platform developed by Northwestern University researchers.
After the onset of the COVID-19 pandemic, significant companies have invested in vaccine development in response to the ongoing pandemic. As a result, gene synthesis markets using vaccine development-based gene synthesis are expected to show positive growth opportunities soon.
Chemotherapy and immunotherapy combined with targeted therapy will grow considerably in the coming years. This would create lucrative opportunities for both established and emerging companies in the healthcare sector. In addition, the focus on molecular-level research will boost demand for gene synthesis over the next few years as clinical research is intensified.
In the near future, synthetic biology may enable the design of microorganisms that are capable of finding cancer cells. Microbes designed for this purpose could secrete toxic proteins that could kill cancer cells with minimal side effects and with precision.
Principal Consultant
Ongoing developments in synthetic DNA technology are gaining popularity as a viable measure to address concerns about the rising pathogens is expected to drive the market growth.
Emergence of novel strains of COVID-19 and growing penetration of targeted therapy are propelling the demand for gene synthesis to assist in characterizing genes. Also, numerous research and development institutes are increasingly adopting gene synthesis techniques to develop highly accurate diagnostics for novel diseases.
For instance, the National Institute of Standards and Technology has announced adopting gene synthesis techniques for producing new synthetic gene fragments from the COVID-19 virus. This would assist the medical testing providers in developing more accurate and reliable diagnostic tests for the disease. A slew of such developments is estimated to favor the growth in the market.
Medical research and academic institutes are supported by strong technological and scientific expertise. They are increasingly focusing on advanced basic research activities, including applied research and synthetic biology, especially when governments prefer cost-effective approaches to conducting development projects.
With a growing demand for advanced recombinant DNA technologies, leading players in the market are extensively aiming at mergers, collaborations, and acquisitions to expand their market. For example, Eurofins Scientific, a leading testing laboratory company, announced the acquisition of a United States-based biotechnology company to expand its gene synthesis capabilities in August 2019.
Hence, increasing research and development activities for novel therapeutics and diagnostics development is expected to augment the growth in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Region | North America |
|---|---|
| Country | United States |
| CAGR (2023 to 2033) | 15.7% |
| Region | Europe |
|---|---|
| Country | United Kingdom |
| CAGR (2023 to 2033) | 21.4% |
| Region | Asia Pacific |
|---|---|
| Country | China |
| CAGR (2023 to 2033) | 29.2% |
| Region | Asia Pacific |
|---|---|
| Country | Japan |
| CAGR (2023 to 2033) | 24.1% |
| Region | Asia Pacific |
|---|---|
| Country | South Korea |
| CAGR (2023 to 2033) | 21.6% |
Rising implementation by drug and diagnostic developers to fuel the gene synthesis demand
As per FMI, the United States is projected to remain a dominant market for gene synthesis in North America between 2023 and 2033.
| Attributes | Details |
|---|---|
| United States Market Expected Size (2033) | USD 1.3 billion |
| United States Market Absolute Dollar Growth | USD 965.8 million |
| CAGR % 2017 to 2022 | 17.6% |
Rising implementation of gene editing and synthesis-related procedures by drug and diagnostic developers in the United States is facilitating the demand for gene synthesis. Growing commercialization of synthetic gene products and increasing authorization by regulatory bodies, like the United States Food and Drug Administration, is anticipated to favor growth. Driven by this, North America is anticipated to create an incremental opportunity of more than half a billion by 2033.
Increasing adoption of molecular engineering to bolster gene synthesis sales
FMI states that the United Kingdom is estimated to emerge as a highly remunerative gene synthesis market in Europe over the assessment period.
Numerous research and development startups in the United Kingdom are pursuing the potential of enzymatic synthesis and shifting their preference towards adopting gene synthesis. Gene synthesis offers higher efficiency and rapid method as compared to traditional chemical means.
| Attributes | Details |
|---|---|
| United Kingdom Market Expected Size (2033) | USD 241.2 million |
| United Kingdom Market Absolute Dollar Growth | USD 206.4 million |
| CAGR % 2017 to 2022 | 25.8% |
It is extensively being used for synthesizing longer DNA sequences and molecular engineering, which is, in turn, propelling the demand for gene synthesis in the market. In addition, several well-established service laboratories and increasing developments in synthetic biology are expected to facilitate growth in the United Kingdom market.
In China, massive developments are happening in the field of genomics. The researchers are focusing on the development of Next Generation Sequencing, which is expected to significantly impact cellular. Direct Genomics, which is a Chinese firm, makes use of single-molecule targeted sequencing to read DNA and RNA. More such developments are expected to increase the application of gene synthesis.
| Attributes | Details |
|---|---|
| China Market Expected Size (2033) | USD 905.3 million |
| China Market Absolute Dollar Growth | USD 835.4 million |
| CAGR % 2017 to 2022 | 28.5% |
China has been witnessing a rapid increase in the adoption of genetic testing. Massive surge in people suffering from chronic diseases has risen the usage of genetic testing. Spur in the availability of direct-to-consumer tests has further propelled the demand for genetic testing. Genetic testing makes use of gene synthesis to identify the nature of the molecule associated with the pathogen.
Increasing focus on novel therapeutics development to augment the sales of gene synthesis service
With growing emphasis on novel therapeutics development, a substantial rise in demand for technologies such as gene synthesis is being observed across various fields. This is particularly observed in recombinant DNA technology, including vaccine development, gene therapy, molecular engineering, and others.
| Attributes | Details |
|---|---|
| Japan Market Expected Size (2033) | USD 477.6 million |
| Japan Market Absolute Dollar Growth | USD 422.6 million |
| CAGR % 2017 to 2022 | 25.4% |
Key players are focusing on collaborating with other companies to provide gene synthesis services to expand their market share. For instance, in 2020, Takeda, a Japan-based pharmaceutical company, announced collaborating with a United States-based protein engineering company, Codexis. The partnership focused on providing gene synthesis services to the latter company for developing novel gene therapies for rare genetic disorders. An assortment of such development is estimated to spur sales in the Japan market.
The key players in South Korea are conducting in-depth research on base editing technology. They are using adenine base editors because of their hyper-compact gene editing technology. These are characterized by compactness in size, which can be delivered using an adeno-associated virus. These are known to have specific and versatile base editing activities. The base editing technology is known to make use of gene synthesis to study the structure of DNA and RNA.
| Attributes | Details |
|---|---|
| South Korea Market Expected Size (2033) | USD 154.8 million |
| South Korea Market Absolute Dollar Growth | USD 132.9 million |
| CAGR % 2017 to 2022 | 21.2% |
The South Korean government is also making massive investments in the biotechnology market. The government announced an allocation of USD 303 million to secure key technologies in the area of biotechnology. This represents massive opportunities for the gene synthesis market.
| Segment | Service Type |
|---|---|
| Attributes | Gene Synthesis Service |
| CAGR (2017 to 2022) | 18.3% |
| CAGR (2023 to 2033) | 16.5% |
| Segment | Application |
|---|---|
| Attributes | Research and Development Activities |
| CAGR (2017 to 2022) | 19.6% |
| CAGR (2023 to 2033) | 18.4% |
Increasing standard and custom gene synthesis applications will favor market growth
FMI revealed that the gene synthesis segment is estimated to exhibit rapid growth in the market, accounting for nearly 75% of the gene synthesis sales by the end of 2033.
Within the segment, custom gene synthesis services are estimated to lead the way, owing to increasing applications across immunology, cancer research, antibody discovery, and others. Apart from this, the guanosine monophosphate (GMP) gene synthesis segment is estimated to account for a significant share.
Growing demand for advanced synthetic biology services to augment the growth of the Research and Development segment
As per FMI, the research and development segment is estimated to hold a significant market share, accounting for more than 35% of the gene synthesis demand by 2033.
Demand for cost-effective and advanced synthetic biology services for double-stranded DNA molecule synthesis is expected to surge the segment's share. Synthetic DNA and RNA genome sequencing, heterologous gene expression, and others are widely used in research and development. Massive investments by governments worldwide in various research projects are also expected to drive market growth.
The start-ups are developing technologies to scale up the production of gene manufacturing technology. For example, they employ a specifically engineered enzyme to enable robust and scalable DNA synthesis. That would allow the one-step generation of long, high-fidelity DNA fragments without limiting the maximum length.
Camena Bioscience: The United States-based start-up enables precise nucleic acid synthesis. The enzymatic de novo synthesis and gene assembly solution developed by the start-up produces long and complex DNA molecules with high accuracy. The technology goes by the name gSynth. It also allows synthetic biology companies to manufacture precise gene variant libraries for protein engineering.
The companies operating in the gene synthesis market are expanding their single-guide RNA manufacturing capabilities. This would certainly enable next-generation gene and cell therapy research and development programs to advance their clinical trials. In December 2022, cell and gene therapy companies leveraged GenScript’s cGMP and sgRNA capability to accelerate speed.
Key developments in the market are:
| Company | Description |
|---|---|
| Twist Bioscience | Twist Bioscience has been working in the service of customers who are changing the world for better. By using the DNA synthetic tools in medicine, agriculture, industrial chemicals, and data storage, the company is looking for ways to drive better lives and sustainability in the planet. The innovative method of DNA production adopted by the company allows in the manufacturing of high-quality synthetic DNA. Twist sets the bar in product quality, meaning the product constantly meets specifications. |
| GenScript | GenScript Biotech Corporation is the world’s leading technology and service provider of life science research and development, and manufacture. The company was founded in New Jersey in 2002, and listed on the Hong Kong Stock Exchange in 2015. GenScript’s business operations span over 100 countries and regions. The company has been providing premium, convenient, and reliable services and products to over 200,000 customers. Driven by the mission, ‘make people and nature healthier through biotechnology’, the company strives to become the most trustworthy biotech firm. |
| ProteoGenix | ProteoGenix was started in 2003 to develop diagnostic assays and biotherapeutics to target proteins discovered by its proteins. The company realized the incredible value of high-quality antibodies and proteins for developing biopharma products. As a service integrator, the ProteoGenix guides its customers from early discovery to the clinic. The main objective of the company is to anticipate future requirements of the biomolecules from the beginning and to subsequently design a sustainable development strategy. |
Other significant gene synthesis companies profiled: Brooks Automation, Inc., Boster Biological Technology
The gene synthesis service holds high revenue potential.
The United States, the United Kingdom, Japan and China are estimated to dominate the global market.
The market is forecast to register a CAGR of 19.2% through 2033.
During 2018 to 2022, the market registered a CAGR of 19.9%.
The growing innovations in product services are increasing current market trends.
1. Executive Summary | Gene Synthesis Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Service Type 5.1. Service 5.1.1. Standard Gene Service 5.1.2. Express Gene Service 5.1.3. Complex Gene Service 5.1.4. Custom Service 5.2. Gene Fragments Service 5.3. GMP Gene Synthesis 5.4. Others 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 6.1. Diagnostics 6.2. Therapeutics 6.3. Research and Development Activities 6.4. Other Application 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 7.1. Academic and Research Institutes 7.2. Biotechnology Companies 7.3. Pharmaceutical Companies 7.4. Contract Research Organisation 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. East Asia 8.5. South Asia 8.6. Oceania 8.7. Middle East and Africa 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. GenScript 18.2. Brooks Automation, Inc. 18.3. Boster Biological Technology 18.4. Twist Bioscience 18.5. ProteoGenix 18.6. Biomatik 18.7. Eurofins Scientific 18.8. ProMab Biotechnologies, Inc. 18.9. Thermo Fisher Scientific, Inc. 18.10. Integrated DNA Technologies, Inc. 18.11. OriGene Technologies, Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Gene Synthesis Market
